Treatments

Therapies, trials, approvals, and access.

Before the Drug, Someone Has to Build the Starting Line

Nine centres across North America are enrolling people whose dreams turn physical. There is no medicine in this study. Its purpose is to assemble the cohort that a future neuroprotection trial would need, and the scaffolding is the point.

A Parkinson's Trial Bets on the Cell's Own Cleanup Crew

Mission Therapeutics has dosed the first Parkinson's patient in a Phase 1b trial of MTX325, an oral drug designed to help brain cells clear out damaged mitochondria, a mechanism distinct from the amyloid and alpha-synuclein targets most other experimental drugs pursue, according to a new ClinicalTrials.gov registration and a company disclosure.

Alzheimer's Gene Therapy Now Has a Factory Problem

A review published this month argues the field's next test is not wider gene expression but proof of dose, coverage in the right cells, primate validation and vector that can be made the same way twice.

Thirty-One Years, 217 Trials, and a Recount of What Failed

A statistics firm screened 6,044 records to re-read every Alzheimer's treatment trial since 1994. Its claim, presented as a conference abstract: some trials written off as failures show hints of benefit, and some hailed as promising look worse. What it does not do is put a number on the years lost.

Under the TMS coil: a Parkinson's trial puts Ayurveda on the record

At a national neurosciences institute in Bengaluru, an exploratory randomized trial is adding a 180-day Ayurvedic regimen to optimized standard Parkinson's care, then measuring cortical excitability, heart-rate variability, cytokines and telomere length. The protocol is now published. The results are not.

Anti-TREM2 Antibody AL002 Fails Completed Phase 2 Trial, Extension Study Halted

A 381-person Phase 2 trial of AL002, an antibody designed to activate the microglial receptor TREM2, ran its full course and did not slow decline in early Alzheimer's disease, according to a peer-reviewed report and the trial's public registration; developer Alector and partner AbbVie have since discontinued the study's long-term extension.

Oral sortilin inhibitor raises progranulin in first-in-human trial, preprint reports

A phase 1a study of VES001 in healthy volunteers, posted as a preprint on 31 March 2026, reports higher progranulin in blood and spinal fluid after seven days of twice-daily capsules. The same drug has since been given to six asymptomatic carriers of GRN mutations, the group whose disease an antibody with the same target failed to slow.